EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Please see below for Important Safety Information for EPCLUSA.
Diagnosing and treating a patient with hepatitis C involves some clear steps. Please refer to the treatment flowchart for guidance on treatment and diagnosis for hepatitis C.
EPCLUSA (sofosbuvir/velpatasvir) is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C genotype 1-6 infection with or without cirrhosis (compensated). In those with advanced cirrhosis (decompensated), EPCLUSA is used with ribavirin.1
Please see our full Prescribing Information or package insert (PI) for complete details.
In patients without cirrhosis or with compensated cirrhosis, EPCLUSA can be taken once daily for 12 weeks with or without food. In patients with decompensated cirrhosis, EPCLUSA is used with ribavirin, which is dosed by weight and taken twice daily with food.1
Learn more about how to take EPCLUSA.
EPCLUSA has a Boxed Warning on the risk of HBV reactivation in HCV/HBV coinfected patients. Hepatitis B (HBV) reactivation has been reported in HCV/HBV coinfected patients who were undergoing or completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Patients should be tested for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA.1
Learn more about the Boxed Warning on the risk of HBV reactivation and EPCLUSA safety.
The ASTRAL clinical trials evaluated the safety and efficacy of EPCLUSA in patients with chronic HCV genotypes 1-6.1
Learn more about the ASTRAL clinical trials and EPCLUSA efficacy and safety. You can also review the full Prescribing Information or package insert (PI) for EPCLUSA (sofosbuvir/velpatasvir) for additional information.
No, EPCLUSA does not contain a protease inhibitor. Sofosbuvir/velpatasvir: The only protease inhibitor–free, pangenotypic, panfibrotic HCV regimen.1,2
Yes. EPCLUSA can be used to treat adults with chronic hepatitis C genotype 1-6 infection with or without cirrhosis (compensated), or with advanced cirrhosis (decompensated) in combination with ribavirin.1
Learn more about EPCLUSA efficacy and safety across levels of liver impairment.
Yes. EPCLUSA can be used to treat chronic HCV in people who inject drugs regardless of active drug use or medication-assisted treatment (MAT).1
Learn more about EPCLUSA efficacy and safety data in people who inject drugs.
Yes. Clinical studies of EPCLUSA included patients on concurrent MAT treatment (methadone and buprenorphine/naloxone).1
Learn more about EPCLUSA efficacy and safety data in people who inject drugs.
Commercial patients may pay as little as $5 per co-pay with EPCLUSA or its Authorized Generic (sofosbuvir/velpatasvir).*
*Terms and conditions apply. See details here.
Learn more about EPCLUSA financial support.
The HCV epidemic continues to grow.4 Learn how treating with EPCLUSA can help make a difference for your chronic HCV patients.
BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.
Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.
BOXED WARNING: RISK OF HEPATITIS B : REACTIVATIONTest all patients for evidence of current or prior hepatitis B virus (HBV)...
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
References: